Announcing Druglike - a Web3 Drug Discovery Platform

druglike.com

Druglike, a Web3 drug discovery software platform co-founded by Martin Shkreli, today released a demo, website, and whitepaper detailing its efforts to democratize the costs, access, and rewards of computational drug discovery.

"We started Druglike because in our experience, traditional drug discovery software is too difficult and expensive to use," said Martin Shkreli, Co-Founder of Druglike. "Druglike will remove barriers to early-stage drug discovery, increase innovation and allow a broader group of contributors to share the rewards."

Shkreli added: "Underserved and underfunded communities, such as those focused on rare diseases or in developing markets, will also benefit from access to these tools."

Druglike is building a decentralized computing network which provides resources for anyone looking to start or contribute to early-stage drug discovery projects. Unlike competitors, Druglike will be web-based and completely free to use. Druglike will soon release a web-based suite for target identification, drug design, and tools for both constructing and running large-scale virtual screening workflows.

Druglike's ability to revolutionize drug discovery is enabled by Web3 technology.

Proof-of-Optimization, a novel blockchain consensus mechanism described in the whitepaper, plans to solve computational chemistry problems at a cost competitive with that of standard on-premises environments and cloud computing. Compute contributors can run both solver and validator nodes powering industrial-scale virtual screening campaigns in exchange for $MSI, the platform's official token.

"For the first time, any computer or phone with access to the web might be responsible and rewarded for discovering the next breakthrough medicine," said Shkreli, Druglike Co-Founder. "We will disrupt the economics of the drug business by allowing a wide pool of innovators and contributors, rather than only pharmaceutical giants, to profit from drug discovery."

"Current in silico software is only accessible to large pharmaceutical companies willing to pay obnoxious licensing fees. Students in every country no matter their university, startup companies to Fortune 500s, and even dedicated hobbyists will all have the same opportunity to design new molecules to change the future of drug discovery," said Shkreli, co-founder of Druglike.


Druglike, a decentralized science (DeSci) drug discovery Web3 platform founded in 2022, seeks to democratize and disrupt the current in silico computational chemistry software industry by offering pharmaceutical researchers, students, and activists access to computational resources and a marketplace to securely work together to create new molecules. Druglike uses Proof-of-Optimization, a novel blockchain consensus mechanism to secure the integrity of shared research. For more information about Druglike, please refer to the white paper at druglike.com


SAFE HARBOR STATEMENT

The information provided in this press release pertaining to Druglike ("the Company"), its business assets, strategy, and operations, is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any assets related to the Company. Information contained in this press release should not be relied upon as advice to buy or do anything. Druglike reserves the right to amend or replace the information contained herein, in part or entirely, at any time. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed in this press release.

Druglike is a blockchain/Web3 software company and not a pharmaceutical company. Druglike is not engaged in pharmaceutical research or drug development.

Statements in this communication that are not historical facts are forward-looking statements that reflect the Company's current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of the Company, including its ability to realize the benefits from our operating model or successfully pursue stated initiatives.  All statements other than historical facts may be forward-looking statements and can be identified by words such as "anticipate," "believe," "could," "design," "estimate," "expect," "forecast," "goal," "guidance," "imply," "intend," "may", "objective," "opportunity," "outlook," "plan," "position," "potential," "predict," "project," "prospective," "pursue," "seek," "should," "strategy," "target," "would," "will," "aim" or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company. While the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of the Company.

CONTACT INFORMATION:
pr@druglike.com

Twitter: https://twitter.com/druglike_io
 

Source: Druglike

Share:


Categories: Cryptocurrency, Healthcare Technology, Scientific Computing

Tags: drug discovery, martin shkreli, pharmaceutical